Scotiabank analyst Nicholas Yulico lowered the firm’s price target on Healthpeak Properties (DOC) to $23 from $24 and keeps an Outperform rating on the shares. The firm is providing updated thoughts on the recent NYC Office sale comparables and commercial mortgage-backed securities, CMBS, issuance, which has led to changes to the ratings of the U.S. Real Estate & REITs in its coverage, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Wedbush upgrades Welltower to Outperform, raises price target to $167
- Healthpeak Properties price target lowered to $24 from $27 at Wedbush
- Healthpeak Properties price target lowered to $24 from $25 at Baird
- Potential Regulatory Changes Threaten Healthpeak Properties’ Investment in Healthcare Real Estate
- Healthpeak Properties: Strong Q4 Performance and Strategic Initiatives Justify Buy Rating